GlassScriptPhysician profile
Philip M George
NPI 1851472070
$912.39
in general payments reported to CMS, 2019-2025
12 companies · $63.30 in 2025
The $63.30 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $278 · 2020: $128 · 2021: $82.24 · 2022: $225 · 2023: $48.71 · 2024: $86.67 · 2025: $63.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $198.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $410.28 | 2020-2022 | |
| W. L. Gore & Associates, INC. | $179.22 | 2019 | |
| Abbott Laboratories | $98.68 | 2019 | |
| Novo Nordisk INC | $37.39 | 2024 | Rybelsus, Ozempic |
| Abbvie INC. | $35.67 | 2023 | |
| Janssen Biotech, INC. | $31.82 | 2024-2025 | Tremfya |
| Avanos Medical | $25.53 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.32 | 2025 | Entyvio |
| Lilly USA, LLC | $23.23 | 2025 | Omvoh |
| Ibsa Pharma INC. | $16.86 | 2024 | Tirosint, Licart, Flector |
| Ardelyx, INC. | $16.35 | 2024 | Ibsrela |
| Ascendis Pharma Endocrinology INC | $13.04 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.